<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00019994</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067391</org_study_id>
    <secondary_id>NCI-99-C-0159</secondary_id>
    <secondary_id>NCI-T99-0079</secondary_id>
    <nct_id>NCT00019994</nct_id>
    <nct_alias>NCT00001833</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>Immunization of Patients With Metastatic Melanoma Using a Class II Restricted Peptide From the GP100 Antigen and Class I Restricted Peptides From the GP100 and MART-1 Antigens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients&#xD;
      who have metastatic melanoma that has not responded to previous therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the clinical response to immunization using gp100:44-59 antigen peptide plus&#xD;
           gp100:209-217 (210M) and MART-1:26-35 (27L) antigen peptides in patients with metastatic&#xD;
           melanoma who are HLA-DRB1*0401 and HLA-A0201 positive.&#xD;
&#xD;
        -  Determine the clinical response to immunization using gp100:44-59 antigen peptide alone&#xD;
           in patients with metastatic melanoma who are HLA-DRB1*0401 positive but HLA-A0201&#xD;
           negative.&#xD;
&#xD;
        -  Determine the immunologic response in patients treated with these regimens as measured&#xD;
           by changes in T-cell precursors from before to after treatment.&#xD;
&#xD;
        -  Evaluate the toxicity profiles of these regimens in these patients.&#xD;
&#xD;
      OUTLINE: Patients are assigned to one of three immunization groups based on HLA-A0201 status&#xD;
      and prior gp100:209-217 (210M) antigen peptide immunization:&#xD;
&#xD;
        -  Group 1 (HLA-A0201 positive and no prior gp100:209-217 [210M] antigen peptide): Patients&#xD;
           receive gp100:44-59 and gp100:209-217 (210M) antigen peptides emulsified together in&#xD;
           Montanide ISA-51 (ISA-51) subcutaneously (SC) and gp100:44-59 and MART-1:26-35 (27L)&#xD;
           antigen peptides emulsified together in ISA-51 SC.&#xD;
&#xD;
        -  Group 2 (HLA-A0201 positive and prior gp100:209-217 [210M] antigen peptide): Patients&#xD;
           receive treatment as in group 1.&#xD;
&#xD;
        -  Group 3 (HLA-A0201 negative and no prior gp100:209-217 [210M] antigen peptide): Patients&#xD;
           receive gp100:44-59 antigen peptide emulsified in ISA-51 SC alone.&#xD;
&#xD;
        -  All groups: Treatment repeats every 3 weeks for 4 doses in the absence of disease&#xD;
           progression or unacceptable toxicity. Patients with complete response after 4 doses&#xD;
           receive a maximum of 2 additional doses. Patients with stable disease or minor, mixed,&#xD;
           or partial response after 4 doses receive a maximum of 12 additional doses. Patients&#xD;
           with no response after 4 doses receive immunization with the same peptides and&#xD;
           interleukin-2 IV over 15 minutes every 8 hours for a maximum of 12 doses beginning 1 day&#xD;
           after each immunization.&#xD;
&#xD;
      Patients are followed at 3-4 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 45-75 patients (15-25 per immunization group) will be accrued&#xD;
      for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1999</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MART-1 antigen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>gp100 antigen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>incomplete Freund's adjuvant</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven metastatic melanoma that has failed standard treatment&#xD;
&#xD;
          -  HLA-DRB1*0401 positive&#xD;
&#xD;
          -  Known HLA-A0201 status&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  16 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 90,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  AST or ALT less than 3 times normal&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No symptomatic cardiac disease&#xD;
&#xD;
        Immunologic:&#xD;
&#xD;
          -  No autoimmune disease&#xD;
&#xD;
          -  No primary or secondary immunodeficiency disease&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active systemic infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior immunization to the entire gp100 molecule&#xD;
&#xD;
          -  At least 3 weeks since prior gp100:209-217 antigen peptide&#xD;
&#xD;
          -  At least 3 weeks since other prior biologic therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 3 weeks since prior endocrine therapy&#xD;
&#xD;
          -  No concurrent steroid therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Prior surgery for cancer allowed&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 3 weeks since any prior therapy except surgery for cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A. Rosenberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Phan GQ, Touloukian CE, Yang JC, Restifo NP, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J Immunother. 2003 Jul-Aug;26(4):349-56.</citation>
    <PMID>12843797</PMID>
  </reference>
  <verification_date>March 2003</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 17, 2013</last_update_submitted>
  <last_update_submitted_qc>June 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

